Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHEK Check-Cap	$0.68	$0.74	$0.56 ▼ $3.04	$3.97M	0.19	28,454 shs	9,285 shs
DRCT Direct Digital	$0.44 -4.1%	$0.54	$0.38 ▼ $6.59	$8.68M	6.04	746,686 shs	365,691 shs
MOLN Molecular Partners	$3.54 -0.7%	$3.71	$3.36 ▼ $7.60	$143.63M	1.1	924 shs	3,190 shs
SLGL Sol-Gel Technologies	$15.25 -1.3%	$9.51	$3.90 ▼ $16.89	$43.05M	1.21	18,485 shs	25,122 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHEK Check-Cap	0.00%	+10.28%	-11.13%	-26.60%	-63.79%
DRCT Direct Digital	-4.14%	+7.82%	-19.28%	-13.34%	-85.90%
MOLN Molecular Partners	-3.94%	-2.46%	-0.48%	-7.92%	-42.97%
SLGL Sol-Gel Technologies	-1.29%	+4.38%	+91.94%	+104.15%	+281.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHEK Check-Cap	0.4185 of 5 stars	0.0	3.0	1.9	0.0	0.6
DRCT Direct Digital	2.7602 of 5 stars	3.5	3.0	1.6	2.5	0.6
MOLN Molecular Partners	2.4571 of 5 stars	3.8	2.0	3.3	0.0	0.6
SLGL Sol-Gel Technologies	2.9438 of 5 stars	3.5	3.0	4.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHEK Check-Cap	0.00	N/A	N/A	N/A
DRCT Direct Digital	3.00	Buy	$6.00	1,263.95% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	239.37% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	162.30% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
DRCT Direct Digital	$62.29M	0.13	N/A	N/A	($1.30) per share	-0.34
MOLN Molecular Partners	$5.65M	25.27	N/A	N/A	$3.99 per share	0.89
SLGL Sol-Gel Technologies	$11.54M	3.69	N/A	N/A	$10.36 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	-$6.24M	-$1.83	N/A	N/A	N/A	-25.99%	N/A	-36.29%	N/A
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	8/15/2025 (Estimated)

Latest SLGL, CHEK, DRCT, and MOLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	H1 2025	MOLN Molecular Partners	-$0.53	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	DRCT Direct Digital	-$0.96	-$0.23	+$0.73	-$0.23	$11.84 million	$10.14 million
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHEK Check-Cap	N/A	N/A	N/A
DRCT Direct Digital	N/A	0.49	0.49
MOLN Molecular Partners	N/A	15.28	15.28
SLGL Sol-Gel Technologies	N/A	5.12	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHEK Check-Cap	1.07%
DRCT Direct Digital	4.02%
MOLN Molecular Partners	26.55%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
CHEK Check-Cap	0.48%
DRCT Direct Digital	62.82%
MOLN Molecular Partners	5.93%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
DRCT Direct Digital	60	18.91 million	7.03 million	Not Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

SLGL, CHEK, DRCT, and MOLN Headlines

Recent News About These Companies

Sol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

April 1, 2025 | tipranks.com

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

February 25, 2025 | zacks.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

February 7, 2025 | finance.yahoo.com

Sol Gel Technologies Ltd (SLGL) Stock Trading Recap

December 26, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL, CHEK, DRCT, and MOLN Company Descriptions

Check-Cap NASDAQ:CHEK

$0.68 0.00 (0.00%)

Closing price 08/14/2025 03:49 PM Eastern

Extended Trading

$0.67 -0.01 (-1.03%)

As of 08/14/2025 04:32 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Direct Digital NASDAQ:DRCT

$0.44 -0.02 (-4.14%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.42 -0.01 (-3.39%)

As of 08/14/2025 07:45 PM Eastern

Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.

Molecular Partners NASDAQ:MOLN

$3.54 -0.02 (-0.67%)

Closing price 08/14/2025 03:50 PM Eastern

Extended Trading

$3.54 0.00 (-0.03%)

As of 08/14/2025 04:04 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Sol-Gel Technologies NASDAQ:SLGL

$15.25 -0.20 (-1.29%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$15.03 -0.22 (-1.44%)

As of 08/14/2025 04:10 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time